Last reviewed · How we verify
NCT03382327: 3D-HAPPI
Benefit of the Use of 3D Models and Tools in Hepatectomy Planning for Hepatocarcinomas
NA trial testing Surgical planning in Hepatocarcinoma in 136 participants. Completed in 16 October 2020.
16 October 2020
Quick facts
| Lead sponsor | IHU Strasbourg |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 136 |
| Start date | 16 October 2017 |
| Primary completion | 16 October 2020 |
| Estimated completion | 16 October 2020 |
| Sites | 12 locations across France |
Drugs / interventions tested
- Surgical planning
Conditions studied
- Hepatocarcinoma — all drugs for Hepatocarcinoma →
Sponsor
IHU Strasbourg — full company profile →
Who can join
18 and older, any sex, with Hepatocarcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of this study is to assess the benefit of 3D models in the planning of hepatic resection by comparing the changes in the surgical plan based on the analysis of conventional preoperative images (CT-scan and MRI), compared to the surgical plan based on the analysis of 3D reconstruction.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03382327
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hepatocarcinoma
Currently open trials in the same condition.
- NCT07432347 — Decoding Epigenetic Mechanisms Driving Immune Evasion in Liver Cancer With Omics Approaches · recruiting
- NCT06886763 — HCC Innervation Assessment · active not recruiting
- NCT06028724 — A Study on the Prevalence of Clinically Useful Mutations in Solid Tumor Characterized by Next Generation Sequencing Meth · recruiting
- NCT05794048 — METabolic PROFILE of Hepatocarcinoma and Pancreatic Tumors · NA · recruiting
- NCT03755739 — Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors · Phase 2, PHASE3 · recruiting
Other IHU Strasbourg trials
Trials by the same sponsor.
- NCT06017427 — Evaluation of Patient Satisfaction During Treatment With Dupilumab in Severe and Recurrent Nasosinusal Polyposis Despite · terminated
- NCT05515705 — First-in-human Navigation Endoscopic Ultrasound (EUS) System Clinical Study · NA · terminated
- NCT05357729 — Safety and Performance Study of the MultiSense® Ambulatory Telemonitoring System for Non-critical Patient Management · NA · completed
- NCT04899739 — Intraoperative Endoscopic Ultrasound for Pancreatic Cancer · NA · completed
- NCT05044585 — Evaluation of RDS MultiSense® in Desaturation Analysis in Healthy Volunteers · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03382327 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by IHU Strasbourg
- Last refreshed: 10 February 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03382327.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing